LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Abstract Poly-ADP Ribose Polymerase (PARP) targeted therapy is clinically approved for the treatment of homologous recombination (HR) repair deficient tumors. The remarkable success of this therapy in the treatment of HR repair deficient cancers has not translated to HR-proficient cancers. Our studi...

Full description

Bibliographic Details
Main Authors: Goutam Dey, Rashmi Bharti, Chad Braley, Ravi Alluri, Emily Esakov, Katie Crean-Tate, Keith McCrae, Amy Joehlin-Price, Peter G. Rose, Justin Lathia, Zihua Gong, Ofer Reizes
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Journal of Ovarian Research
Online Access:https://doi.org/10.1186/s13048-023-01194-2

Internet

https://doi.org/10.1186/s13048-023-01194-2

Similar Items